Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TRP

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: TRP. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-000604-16 Sponsor Protocol Number: ARD6772 Start Date*: 2006-08-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites.
    Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005059-10 Sponsor Protocol Number: Trp-IBD Start Date*: 2018-09-14
    Sponsor Name:Ghent University Hospital
    Full Title: Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005026-31 Sponsor Protocol Number: EFC6125 [AVE0005A/3001] Start Date*: 2006-04-24
    Sponsor Name:Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with ...
    Medical condition: pacientes con cáncer de ovario avanzado con ascitis maligna sintomática recurrente
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) HU (Completed) AT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001972-36 Sponsor Protocol Number: CSOM230C2305 Start Date*: 2007-11-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, blinded study to assess the safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly.
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) BE (Completed) GB (Completed) GR (Completed) IT (Completed) ES (Completed) NL (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) PT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001845-13 Sponsor Protocol Number: Y-47-52120-722 Start Date*: 2005-02-17
    Sponsor Name:Beaufour Ipsen Pharma S.A.S.
    Full Title: A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patien...
    Medical condition: Upper back myofascial pain syndrome (MPS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10048780 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002360-14 Sponsor Protocol Number: AK-2016-HHC1 Start Date*: 2016-09-29
    Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer
    Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073040 Metastatic oropharyngeal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030961 Oral cancer stage unspecified LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028801 Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001863-64 Sponsor Protocol Number: AP301-II-001 Start Date*: 2012-07-03
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury
    Medical condition: Acute Pulmonary oedema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003930-10 Sponsor Protocol Number: KEKU1 Start Date*: 2018-01-12
    Sponsor Name:Recherche et enseignement en douleur, anesthesie reanimation
    Full Title: KETAMINE'S EFFICIENCY IN THE TREATMENT OF CHRONIC PAIN WITH INFLAMMATORY COMPONENT: EXPLORING THE KYNURENIN PATHWAYS. A controlled, placebo-controlled, double-blind trial.
    Medical condition: The population selected is a spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months) Adult, spinal cord injury (SCI...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016921-32 Sponsor Protocol Number: HSJD-OB-TRP Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002184-34 Sponsor Protocol Number: AK-2016-PC-1 Start Date*: 2016-09-14
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
    Full Title: Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003049-24 Sponsor Protocol Number: PHY201501 Start Date*: 2016-07-27
    Sponsor Name:Uppsala University, Department of Medical Sciences
    Full Title: The Precision Hypertension Care study
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002417-21 Sponsor Protocol Number: AK2016-2 Start Date*: 2016-09-22
    Sponsor Name:Rigshospitalet
    Full Title: uPAR-PET/MR in glioma
    Medical condition: Gliomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016722-13 Sponsor Protocol Number: CSOM230C2402 Start Date*: 2010-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanr...
    Medical condition: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular diseas...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) NO (Completed) BE (Completed) DE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000600-29 Sponsor Protocol Number: UX023-CL301 Start Date*: 2016-09-15
    Sponsor Name:Ultragenyx Pharmaceuticals Inc
    Full Title: A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)
    Medical condition: X-linked hypophosphatemia (XLH) is a disorder of renal phosphate wasting, defective bone mineralisation, and impaired growth plate or endochondral ossification caused by inactivating mutations in t...
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) IE (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002849-12 Sponsor Protocol Number: CSOM230B2201E1 Start Date*: 2005-01-12
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and...
    Medical condition: Acromegaly is a rare, serious condition characterized by chronic hypersecretion of GH (growth hormone) caused in over 95% of patients by a GH-secreting pituitary adenoma. Clinical manifestations ar...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10000599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000998-39 Sponsor Protocol Number: TIDE-13-22 Start Date*: 2014-10-30
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. el...
    Medical condition: Chemotherapy Induced Diarrhea (CID)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10056985 Diarrhoea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001026-33 Sponsor Protocol Number: AK2016-1 Start Date*: 2016-06-08
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: uPAR PET/CT and FDG PET/MRI for preoperative staging of bladder cancer
    Medical condition: Urinary bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10005004 Bladder cancer NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004503-23 Sponsor Protocol Number: CS-2015-1 Start Date*: 2015-12-17
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
    Full Title: Phase II trial: uPAR-PET for preoperative staging of breast cancer patients
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:40:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA